Use your antibodies-online credentials, if available.
Keine Produkte auf Ihrer Vergleichsliste.
Ihr Warenkorb ist leer.
Weitere Synonyme anzeigen
Wählen Sie die gewünschte Spezies
Human HER2 Protein expressed in Human Cells - ABIN2001860
Yamamoto, Ikawa, Akiyama, Semba, Nomura, Miyajima, Saito, Toyoshima: Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor. in Nature 1986
Show all 9 Pubmed References
Human HER2 Protein expressed in Wheat germ - ABIN1353011
He, Qu, Shen, Tan, Zeng, Liu, Jiang, Li: Highly specific recognition of breast tumors by an RNA-cleaving fluorogenic DNAzyme probe. in Analytical chemistry 2015
Show all 2 Pubmed References
Human HER2 Protein expressed in HEK-293 Cells - ABIN2181214
NDong, Tate, Kett, Batra, Demidenko, Lewis, Hoopes, Gerngross, Griswold: Tumor Cell Targeting by Iron Oxide Nanoparticles Is Dominated by Different Factors In Vitro versus In Vivo. in PLoS ONE 2015
Show all 4 Pubmed References
Human HER2 Protein expressed in Human Cells - ABIN2001858
Lai, Lemke: An extended family of protein-tyrosine kinase genes differentially expressed in the vertebrate nervous system. in Neuron 1991
Show all 6 Pubmed References
Human HER2 Protein expressed in HEK-293 Cells - ABIN2181216
Piechocki, Wu, Jones, Jacob, Gibson, Ethier, Abrams, Yagita, Venuprasad, Wei: Induction of proapoptotic antibodies to triple-negative breast cancer by vaccination with TRAIL death receptor DR5 DNA. in International journal of cancer. Journal international du cancer 2012
Show all 4 Pubmed References
The growth and chemo-resistance of Prostate cancer cells may be suppressed via re-expression of miR-4319 that inhibits Her-2 and its signaling.
Expression of p16 may be used as a prognostic factor of overall survival and stage of ovarian carcinoma, while HER2 expression may not be used as a prognostic factor of overall survival.
AhR is an important factor for the malignancy in HER2 overexpressing breast cancers.
Alcohol is associated with lower risk of H2E breast cancer relative to ER+ breast cancer.
In this study, we focused on patients with gastric cancer who received preoperative chemotherapy and aimed to examine the changes in HER2 expression status and amplification of EGFR and MET, not only after HER2-targeted therapy, but also after cytotoxic chemotherapy alone.
Trastuzumab in combination with docetaxel and S-1 showed effective antitumor activity and manageable toxicities as first-line treatment for patients with HER2-positive gastric cancer
Findings show a network of deregulated exosomal miRNAs with specific expression patterns in exosomes of HER2-positive and TNBC patients that are also associated with clinicopathological parameters and pCR within each BC subtype.
High HER2/EIF2C1 ratio is associated with breast cancer.
estimates for gene-expression (GE) were added for ER (gene ESR1), for PGR (gene PGR) and for HER2 (gene ERBB2). Combined results were obtained in each patient via a scoring system based on all three receptors
Data show that the caveolin-1 (CAV1) protein is involved in epidermal growth factor receptor 2 (HER2) cell membrane dynamics within the context of receptor endocytosis.
Clinical confirmation of our machine learned Bayesian networks will have significant impact on our understanding of the role of NRF1 as a valuable biomarker for breast cancer diagnosis and prognosis as well as provide strong rationale for future studies to develop NRF1 signaling-based therapeutics to target HER2+ breast cancer.
The Stop & Go study aimed to determine if an intermittent treatment regimen with paclitaxel plus bevacizumab was not inferior in terms of PFS to a continuous regimen, both in combination with bevacizumab maintenance treatment, in first-line treatment of patients with HER2-negative, advanced breast cancer.
these results pinpoint transaldolase as a novel metabolic enzyme possessing synthetic lethality with HER2 inhibition.
the estrogen receptor (ER) and progesterone receptor (PR), as well as human epidermal growth factor receptor 2 (Her2neu) expressions in breast tumor cells, were evaluated.
This abnormally sensitive electrochemical sensing performance resulting from anionic porphyrin for DNA sequences specific to HER2 gene will offer considerable promise for tumor diagnosis and treatment
Authors showed that mRNA and protein levels of COX2 and HER2 were upregulated in CRC compared with the adjacent tissues. COX2 protein levels and nuclear COX2 expression were correlated with a poor prognosis of CRC patients. COX2 expression was positively associated with HER2 expression.
In patients with HER2-positive advanced breast cancer who have been heavily pretreated with anti-HER2 agents and cytotoxic chemotherapy, trastuzumab emtansine (T-DM1) is well tolerated and provided a meaningful progression-free survival of 6 months and an overall survival that has not been reached.
The expression of C-Met and HER2 protein in lung adenocarcinoma is highly correlated, and whether it is synergistic in the targeted therapy of lung adenocarcinoma deserves further study.
Although ST6GalI overexpression increased HER2 sialylation, corresponding to decreased HER2 phosphorylation, high alpha2,6sialylation enhanced Akt and ERK phosphorylation levels compared to those in the vector cell line; ST6GalI knockdown had the opposite effects. Collectively, these results implicated a functional role of ST6GalI in promoting tumor cell progression and trastuzumab resistance.
Study demonstrate that the miR-495 exerts promotive effects on GC chemosensitivity via inactivation of the mTOR signaling pathway by suppressing ERBB2. The study provides reliable evidence supporting the use of miR-495 as a novel potential target in the chemotherapy of GC.
High HER2 expression is associated with metastasis in breast Cancer.
Study shows that within endoplasmic reticulum-related subsurface cistern, sigma-1 receptors, Kv2.1 and neuregulin-1 are clustered in highly specific, non-overlapping, microdomains, whereas ErbB2 and ErbB4 are present in the adjacent presynaptic compartment. This organization may define highly ordered and spatially restricted sites for different signal-transduction pathways.
ErbB2 interacts with Nrp1 to form a Sema3d co-receptor expressed by developing coronary endothelium and required for proper connections of the forming coronary veins to the right atrium.
The objective of this study was to determine if loss of Stard13 plays a role in mammary tumor progression using transgenic mice expressing the activated ErbB-2 (Neu) oncogene and Cre recombinase (NIC) in mammary epithelium under transcriptional control of the murine mammary tumor virus (MMTV) promoter (MMTV-NIC).
Over-expression of HER2 remarkably enhanced the proliferation, invasion and migration of B16 cells.
YAP accumulated in nuclei of mammary glands in ErbB2/EGFR-transgenic mice, suggesting that EGFR signaling affects YAP in vivo similar to cell culture. ErbB2/EGFR-transgenic mice develop mammary tumors in 7-8 months, but surprisingly, MaSCs from these mice did not form tumors when transplanted into host mice.
Results indicate the importance of the LDL receptor (LDLR) in the growth of triple-negative and HER2-overexpressing breast cancers in the setting of elevated circulating LDL cholesterol (LDL-C).
caErbB2 markedly enhances regeneration of damaged dorsal roots, while evoking little change in intact roots
immunocompetent mouse models of HER2/ErbB2-driven breast cancer, CD73 expression by tumor cells and host cells significantly suppressed immune-mediated responses mediated by anti-ErbB2 mAb.
We further demonstrate that loss of one allele of PTEN is sufficient to shift isoform dependency from p110alpha to p110beta in vivo. These results provide insight into the molecular mechanism by which ErbB2-positive breast cancer escapes p110alpha inhibition.
sought to further echocardiographically characterize the ErbB2(tg) mouse line as a model of hypertrophic obstructive cardiomyopathy
investigations revealed that NUMB and NUMBL interacted with small GTPase Rab7 to transition ERBB2 from early to late endosome for degradation.
Combined targeting of TGF-beta, EGFR and HER2 signaling suppresses lymphangiogenesis and metastasis in a pancreatic ductal adenocarcinoma model.
The conjugation of benzylguanine-modified auristatin F to EGFR-specific 425(scFv)-SNAP and HER2-specific alphaHER2(scFv)-SNAP resulted in two potent recombinant antibody-drug conjugates that specifically killed breast cancer cell lines by inducing apoptosis when applied at nanomolar concentrations.
ErbB2 is required for neonatal cardiomyocyte proliferation. ErbB2 conditional knockout heart exhibited an upregulation of negative cell cycle regulators.
Despite previous evidence suggesting that ErbB receptors can bind and activate IRSs, our findings indicate that ErbB2 does not cooperate with the IRS pathway in mouse breast cancer model.
It was suggested that transgenic HER-2/neu involves in initiation of malignization of mammary epithelial cells but also in acceleration of age-related hormonal and metabolic changes in turn promoting mammary carcinogenesis
Study showed that suppression of STAT3, STAT5, and STAT6 and overexpression of the proapoptotic factor STAT1, which provides p53-mediated apoptosis, are the causes for increasing the number of apoptotic neurons in physiological aging. HER-2 tyrosine kinase receptor overexpression promotes neuronal survival through activation of STAT-signaling pathway with simultaneous suppression of the proapoptotic factor STAT1
that myocardial ErbB2 and beta-adrenergic receptors signalling are linked in a feedback loop with beta-adrenergic receptors activation leading to increased ErbB2 expression and activity
Metformin inhibits breast tumor angiogenesis and suggest role of HIF-1alpha-VEGF signaling axis in mediating HER2-induced tumor angiogenesis.
Newly synthesized N-cadherin molecules move from the lateral to the basal surface of cardiomyocytes during trabeculation. This localization requires Erbb2 signaling.
these results suggest that Nrg1 is not the primary effector of trabeculation and/or that other EGF-like ligand(s) activates the ErbB2/ErbB4 pathway, either through functioning as the primary ligand or acting in a redundant manner. Overall, our work provides an example of cross-species differences in EGF family member requirements for an evolutionary conserved process.
Embryos homozygous for a GBT insertion within neuregulin 2a (nrg2a) revealed a novel requirement for a Neuregulin 2a (Nrg2a)-ErbB2/3-AKT signaling pathway governing the organization of a subset of epidermal cells during median fin fold morphogenesis.
A direct link was found between Erbb2 activity and remodeling of myofibrils.
Study shows that, in addition to its role in cardiomyocyte proliferation, ErbB2 is also required for regulating cardiomyocyte migration (delamination) to initiate cardiac trabeculation.
erbb3 and erbb2 are essential for schwann cell migration and myelination in zebrafish.
NRG1 and PI3K functionally interact with ErbB2 and ErbB3 during regeneration
Results indicated that most periocular squamous cell carcinomas of horses expressed epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2).[HER2]
Widespread expression of ErbB2 receptor mRNAs was found throughout the telencephalon of juvenile and adult monkeys with in situ hybridization, with higher levels in grey matter compared to white matter.
We have isolated the cDNA encoding the rhesus monkey homolog of human Her2/neu (RhErbB2) to construct DNA plasmids and adenoviral vectors for the development of a cancer vaccine against this protein.
This gene encodes a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. This protein has no ligand binding domain of its own and therefore cannot bind growth factors. However, it does bind tightly to other ligand-bound EGF receptor family members to form a heterodimer, stabilizing ligand binding and enhancing kinase-mediated activation of downstream signalling pathways, such as those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase. Allelic variations at amino acid positions 654 and 655 of isoform a (positions 624 and 625 of isoform b) have been reported, with the most common allele, Ile654/Ile655, shown here. Amplification and/or overexpression of this gene has been reported in numerous cancers, including breast and ovarian tumors. Alternative splicing results in several additional transcript variants, some encoding different isoforms and others that have not been fully characterized.
c-erb B2/neu protein
, metastatic lymph node gene 19 protein
, neuro/glioblastoma derived oncogene homolog
, neuroblastoma/glioblastoma derived oncogene homolog
, proto-oncogene Neu
, proto-oncogene c-ErbB-2
, receptor tyrosine-protein kinase erbB-2
, tyrosine kinase-type cell surface receptor HER2
, v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog
, Neu oncogene
, avian erythroblastosis oncogene B 2
, proto-oncogene NEU
, Avian erythroblastosis viral (v-erb-B2) oncogene homologue 2 (neuro/glioblastoma derived oncogene homolog)
, NEU proto-oncogene
, epidermal growth factor receptor-related protein
, v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2
, epidermal growth factor receptor type 2